Characterization of Drug Resistance Patterns, Mutation Profiles and Prevalence of Mycobacterium tuberculosis in Shaoxing

绍兴结核分枝杆菌耐药模式、突变谱及流行情况特征分析

阅读:2

Abstract

OBJECTIVE: This study aimed to analyze drug resistance patterns, mutation profiles in Mycobacterium tuberculosis isolates and clinical characteristics of tuberculosis patients in Shaoxing, Zhejiang, China. METHODS: Clinical specimens and data from tuberculosis patients admitted in 2024 were collected. Cultures were established using the MGIT liquid culture system, and drug susceptibility to twelve anti-tuberculosis agents (four first-line and eight second-line) was assessed by the microbroth dilution method. Mutations in the rpoB gene, katG gene, and inhA promoter were identified using a DNA microarray chip assay. RESULTS: Among 268 Mycobacterium tuberculosis isolates, 62 (23.1%) exhibited resistance to at least one anti-tuberculosis drug. These comprised 21 (7.8%) mono-resistant, 25 (9.3%) poly-resistant, and 16 (6.0%) multidrug-resistant strains, including 3 (1.1%) classified as pre-extensively drug-resistant and 1 (0.4%) as extensively drug-resistant. Among rifampicin-resistant isolates, mutations at codons 531 (47.4%) and 526 (21.1%) of the rpoB gene were most frequent, while the katG Ser315Thr substitution was detected in 44.8% of isoniazid-resistant strains. Compared with primary cases, re-treated patients were more frequently over 50 years of age, exhibited a higher prevalence of pulmonary cavities, and showed significantly elevated rates of drug resistance (P < 0.05). CONCLUSION: Our findings indicate that although the overall prevalence of drug-resistant tuberculosis in Shaoxing remains low, the resistance patterns are heterogeneous. These results underscore the need for comprehensive drug susceptibility and genetic testing to guide effective treatment strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。